Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 194 results for sepsis

  1. Faecal microbiota transplant for recurrent Clostridium difficile infection (HTG338)

    Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridium difficile infection. This involves introducing enteric bacteria from the faeces of healthy donors to restore a healthy balance of bacteria in the gut.

  2. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

  3. RespiraSense for continuously monitoring respiratory rate (MIB299)

    NICE has developed a medtech innovation briefing (MIB) on RespiraSense for continuously monitoring respiratory rate .

  4. Negative pressure wound therapy for the open abdomen (HTG321)

    Evidence-based recommendations on negative pressure wound therapy for the open abdomen. This involves using a small pump to remove infected material, stop fluid escaping and help the wound heal.

  5. Inducing labour (NG207)

    This guideline covers the circumstances for inducing labour, methods of induction, assessment, monitoring, pain relief and managing complications. It aims to improve advice and care for pregnant women who are thinking about or having induction of labour.

  6. Abortion care. Patient decision aid on choosing between medical or surgical abortion before 14 weeks

    These serious complications include severe bleeding, damage to the womb or sepsis (a severe reaction to an infection). The risk of...

  7. Fallopian tube recanalisation by guidewire (HTG44)

    Evidence-based recommendations on fallopian tube recanalisation by guidewire. This involves injecting dye through a narrow tube inserted into the fallopian tube and if this does not unblock it, using a guidewire.

  8. Drotrecogin alfa (activated) for severe sepsis (TA84)

    November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.

  9. Bioprosthetic plug insertion for anal fistula (HTG528)

    Evidence-based recommendations on bioprosthetic plug insertion for anal fistula in adults. This involves putting a plug into the fistula and stitching it in place.

  10. Balloon angioplasty of pulmonary vein stenosis in infants (HTG46)

    Evidence-based recommendations on balloon angioplasty of pulmonary vein stenosis in infants. This involves involves inflating a balloon in the narrow section of the pulmonary vein to widen the area so blood can flow through more easily.

  11. Forward view - our priority topics

    Our forward view highlights the topics we will prioritise in the coming year.

  12. Collagen paste for closing an anal fistula (HTG512)

    Evidence-based recommendations on collagen paste for closing an anal fistula in adults. This involves using the paste to fill the fistula to seal it. The aim is to encourage healing.

  13. Otitis media (acute): antimicrobial prescribing (NG91)

    This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.

  14. Percutaneous thoracic duct embolisation for persistent chyle leak (HTG666)

    Evidence-based recommendations on percutaneous thoracic duct embolisation for persistent chyle leak. In this procedure, under general anaesthesia, ultrasound and X-rays are used to create an image of the thoracic duct and find the leak. Then, using a needle, a tube is inserted through the abdominal wall (percutaneous) and guided into the thoracic duct. Small metal coils and medical glue are inserted through the tube and used to plug the leak (embolisation). The aim is to stop the leak.